Setting new standards in drug discovery of immuno-oncology therapeutics:
With the newly patented process for the production of complex arrays, BioCopy is setting new standards in the state of the art. Especially for kinetic measurements of molecular interactions in high-throughput, a simple, resource-efficient method is elementary. The German Patent Office granted the patent for the BioCopy technology much earlier than usual thanks to its great inventive merit.
Bio-Copy's new process requires little effort and saves resources. Arrays with thousands of molecular complexes cannot be made with current state of the art technology. The results are impressive in the truest sense of the word. Molecular complexes can be clearly separated and presented on the surface of the microarray. The cavity structure of the chip (see picture) is reproduced one-to-one on the array. The individual measuring spots (150 µm), which are loaded with molecular complexes during the process, remain clearly separated from each other.
The patent grant not only secures BioCopy the exclusive rights to market its proprietary technology. It is also proof of the great innovative merit of this technology for the development of immuno-oncological therapeutics.
Due to the 'fresh' application of the molecules, there is no loss of quality. This reduces preparation time, guarantees clean measurements and provides high quality results of the binding kinetics.
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier EMA CHMP acknowledges that n
LubioScience GmbH, Switzerland’s leading Life Sciences platform, expands its product portfolio with the addition of fresh human blood products and biospecimens provided by Research Donors from the UK.
Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024 Topline results from the completed Phase I/II will be reported in the first half of 2024
InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces that the company's most advanced artificial intelligence platform has uncovered novel cellular signaling modes of action which enable InterAx to design efficacious orally available drugs for diabetes, obesity, and immuno oncology. Particularly promising results are coming from the
Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements The company is looking to expand development and commercial collaborations with industry leaders
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1